| Literature DB >> 35877220 |
Yudai Hirano1,2, Yuki Shinya1, Toshiya Aono1, Hirotaka Hasegawa1, Mariko Kawashima1, Masahiro Shin2, Hirokazu Takami1, Shunsaku Takayanagi1, Motoyuki Umekawa1, Masako Ikemura3, Tetsuo Ushiku3, Kazuki Taoka4, Shota Tanaka1, Nobuhito Saito1.
Abstract
Stereotactic frame-based brain tumor biopsy (SFB) is a potent diagnostic tool considering its minimal invasiveness, though its diagnostic power and safety for brainstem lesions remain to be discussed. Here, we aimed to examine the usefulness of SFB for brainstem tumors. Twenty-two patients with brainstem tumors underwent 23 SFBs at our institution during 2002-2021. We retrospectively analyzed patient characteristics, tumor pathology, surgical procedures, and outcomes, including surgery-related complications and the diagnostic value. Seven (32%) tumors were located from the midbrain to the pons, eleven (50%) in the pons only, and four (18%) from the pons to the medulla oblongata. The target lesions were in the middle cerebellar peduncles in sixteen procedures (70%), the cerebellum in four (17%), the inferior cerebellar peduncles in two (9%), and the superior cerebellar peduncles in one (4%). A definitive diagnosis was made in 21 patients (95%) at the first SFB. The diagnoses were glioma in seventeen (77%) cases, primary central nervous system lymphoma in four (18%), and a metastatic brain tumor in one (5%). The postoperative complications (cranial nerve palsy in three [13%] cases, ataxia in one [4%]) were all transient. SFB for brainstem tumors yields a high diagnostic rate with a low risk of morbidity.Entities:
Keywords: brainstem tumor; frame-based; stereotactic biopsy
Mesh:
Year: 2022 PMID: 35877220 PMCID: PMC9318548 DOI: 10.3390/curroncol29070360
Source DB: PubMed Journal: Curr Oncol ISSN: 1198-0052 Impact factor: 3.109
Figure 1A 60-year-old man presented with headache, diplopia, and ataxia (Case 18). (a,b) Magnetic resonance imaging (MRI) and positron emission tomography (PET) revealed a pontine tumor extending also to the right thalamus, bilateral medial temporal lobe, right mesencephalic tegmentum, medulla oblongata, and bilateral cerebellum (maximum diameter: 37 mm, tumor volume: 17.8 mL); the surgical trajectories are set through the right middle cerebellar peduncle to the brainstem tumor, aiming for postoperative neurological preservation by using the FrameLink software installed in StealthStation S7 surgical navigation system (Medtronic plc); (c) Surgical setup for stereotactic frame-based biopsy (SFB) of a brainstem tumor. The physical characteristics of this patient are a large head size, short neck, and well-developed occipital muscles. The frame was fixed at four points on the forehead and back of the head by shifting the frontal pins slightly upward from the orbitomeatal baseline (arrow), to reduce the possibility of interference with the surgical field, which comprised a skin incision and burr hole; (d) No hemorrhage was observed on the MRI performed within 24 h after surgery. The tumor specimen was obtained from the targeted location (right middle cerebellar peduncle; arrowhead); (e) Histologic features of a diffuse midline glioma. Hematoxylin and eosin staining showing the diffuse growth of atypical glia cells with round nuclei; (f) Immunohistologic staining showing that the atypical cells are positive for H3K27M.
Summary of stereotactic tumor biopsies of neoplastic lesions in the brainstem.
| No. | Age, Sex | Tumor Location | Target | Diagnosis | Stealth Imaging | PET/SPECT | Follow-Up | Latest mRS | Complications | Postoperative Treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 y, F | Pons | Middle CP | Astro, | CT | Yes | 33 months | 5 | Facial nerve palsy | Chemo, RT |
| 2 | 6 y, F | Midbrain | Middle CP | GBM | CT | No | 1 month | 6 | None | RT |
| 3 | 11 y, F | Midbrain | Middle CP | Astro, | CT | Yes | 9 months | 6 | None | Chemo, RT |
| 4 | 13 y, M | Pons | Middle CP | Astro, | MRI | Yes | 12 months | 6 | None | Chemo, RT |
| 5 | 21 y, M | Midbrain | Middle CP | Astro, | MRI | Yes | 29 months | 6 | None | Chemo, RT |
| 6 | 22 y, M | Pons | Middle CP | Astro, | MRI | No | 61 months | 6 | None | Chemo, RT |
| 7 | 28 y, M | Pons | Inferior CP | Astro, | MRI | Yes | 39 months | 6 | None | Chemo, RT |
| 8 | 34 y, M | Midbrain | Middle CP | Astro, | MRI | Yes | 17 months | 5 | None | Chemo, RT |
| 9 | 34 y, M | Pons | Middle CP | Metastatic | MRI | Yes | 1 month | 5 | Abducens nerve palsy | RT |
| 10 | 34 y, M | Pons | Middle CP | DMG | MRI | Yes | 39 months | 1 | None | Chemo, RT |
| 11 | 38 y, F | Pons | Cerebellum | PCNSL | MRI | Yes | 19 months | 6 | None | Chemo, RT |
| 12 | 38 y, M | Pons | Inferior CP | Astro, | MRI | Yes | 86 months | 2 | Diplopia | Chemo, RT |
| 13 | 39 y, F | Pons | Middle CP | Astro, | MRI | Yes | 8 months | N/A | None | Chemo, RT |
| 14 | 47 y, F | Pons | Middle CP | DMG | MRI | Yes | 7 months | 6 | None | Chemo, RT |
| 15 | 47 y, M | Pons | Middle CP | Astro, | MRI | Yes | 28 months | 2 | None | Chemo, RT |
| 16 | 48 y, M | Midbrain | Middle CP | Astro, | MRI | Yes | 16 months | 4 | None | Chemo, RT |
| 17 | 54 y, F | Pons | Cerebellum | PCNSL | MRI | Yes | 13 months | 6 | None | Chemo, RT |
| 18 | 60y, M | Midbrain | Middle CP | DMG | MRI | Yes | 36 months | 5 | None | Chemo, RT |
| 19-1 | 62 y, M | Pons | Cerebellum | N/A | MRI | Yes | 6 months | N/A | None | Chemo, RT |
| 19-2 | 62 y, M | Pons | Superior CP | GBM | MRI | Yes | 6 months | 6 | Ataxia | Chemo, RT |
| 20 | 65 y, F | Pons | Cerebellum | PCNSL | MRI | Yes | 88 months | 1 | None | Chemo, RT |
| 21 | 70 y, F | Midbrain | Middle CP | PCNSL | MRI | No | 22 months | 6 | None | Chemo, RT |
| 22 | 70 y, M | Pons | Middle CP | Astro, | MRI | Yes | 9 months | 1 | None | Chemo, RT |
Astro: astrocytoma, CP: cerebellar peduncle, CT: computed tomography, DMG: diffuse midline glioma, F: female, GBM: glioblastoma, Gr: grade, M: male, MRI: magnetic resonance imaging, mRS: modified Rankin Scale, mt: mutant, N/A: not available, PCNSL: primary central nervous system lymphoma, PET: positron emission tomography, RT: radiation therapy, SPECT: single-photon emission computed tomography.